Terns Pharmaceuticals (TERN) up 13.6% YTD with promising pipeline advancements.

From Nasdaq: 2024-06-19 13:27:00

Terns Pharmaceuticals, Inc. (TERN) is experiencing a successful year with shares up 13.6% year to date, outperforming the industry’s decline of 7%. The company’s positive momentum is driven by advancements in its oncology and obesity pipeline, including promising data from its allosteric BCR-ABL inhibitor, TERN-701, showing superior efficacy compared to traditional treatments.

TERN-701, Terns’ oral BCR-ABL inhibitor, is showing promise in treating chronic myeloid leukemia (CML) with ongoing phase I studies demonstrating superior efficacy and safety compared to existing treatments. The company expects interim data from the initial dose escalation cohorts of the CARDINAL study in CML by the second half of 2024.

In addition to TERN-701, Terns is evaluating other pipeline candidates like TERN-601 for obesity and TERN-501 for metabolic diseases. The company’s focus on developing innovative small molecule therapeutics for unmet medical needs underscores its potential for future growth and success in the biopharmaceutical industry.

Apart from TERN-701, Terns’ other pipeline candidates, like TERN-601 and TERN-501, also show promise in addressing obesity and metabolic diseases. These developments highlight the company’s commitment to advancing novel therapeutics for critical health conditions and its potential for future growth and success in the biopharmaceutical sector.

Investors are advised to keep an eye on Terns Pharmaceuticals, Inc. (TERN) as the company’s pipeline momentum and positive data readouts could drive continued interest and support its growth trajectory in the competitive biopharmaceutical landscape. The focus on innovative treatments for diseases like CML, obesity, and metabolic disorders positions Terns as a key player in the industry’s ongoing advancements and developments.



Read more at Nasdaq: Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?